Alzheimer’s disease
Researchers with the University of Cambridge in the UK for the first time leveraged human data to quantify the speed of various processes in the brain that lead to Alzheimer’s disease.
The annual Clinical Trials on Alzheimer’s Disease conference is scheduled for November 9-12, and Biogen plans to present data on its portfolio, including its controversial Aduhelm.
This novel diagnostic technology uses augmented reality and a smartphone or tablet to administer cognitive and functional tests.
The 643-participant study failed to reach statistical significance in its co-primary cognitive and functional endpoints, ADAS-Cog11 and ADCS-ADL, at end of treatment.
Nuravax is developing an Alzheimer’s vaccine to induce therapeutically potent concentrations of antibodies against pathological proteins. Know more here.
Late Thursday, Athira announced that Kawas had resigned from her position as CEO and president of the company.
Biogen’s Aduhelm (aducanumab) reported only $300,000 in third-quarter sales compared to original analyst average estimates of $10.79 million.
The NIH revealed that bumetanide, a drug typically used as a diuretic, maybe a potential treatment for those genetically at risk for Alzheimer’s. Know more about it here.
Roche’s candidate drug for Alzheimer’s treatment received breakthrough therapy designation which has increased its chance of getting full FDA approval.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
PRESS RELEASES